<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prognosis of the obesity hypoventilation syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prognosis of the obesity hypoventilation syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prognosis of the obesity hypoventilation syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas J Martin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Safwan Badr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Obesity hypoventilation syndrome (OHS; "pickwickian syndrome") exists when an individual with obesity (body mass index [BMI] &gt;30 kg/m<sup>2</sup>) has awake alveolar hypoventilation (arterial carbon dioxide tension [PaCO<sub>2</sub>] &gt;45 mmHg) which cannot be attributed to other conditions (eg, neuromuscular disease). Untreated OHS is a progressive disorder that is associated with significant morbidity such that prompt recognition and treatment is critical.</p><p>The treatment and prognosis of OHS are reviewed here. The clinical manifestations, diagnosis, complications, and pathogenesis of OHS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7698.html" rel="external">"Clinical manifestations and diagnosis of obesity hypoventilation syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/7697.html" rel="external">"Epidemiology and pathogenesis of obesity hypoventilation syndrome"</a>.)</p><p class="headingAnchor" id="H710310383"><span class="h1">FIRST-LINE THERAPY</span><span class="headingEndMark"> — </span>Noninvasive positive airway pressure (PAP) together with weight loss are the initial first-line therapies for patients with OHS [<a href="#rid1">1</a>]. A comprehensive and multidisciplinary approach utilizing experts in obesity, sleep, and pulmonary medicine is recommended.</p><p class="headingAnchor" id="H2738498"><span class="h2">Positive airway pressure</span><span class="headingEndMark"> — </span>All patients with OHS have some form of sleep-disordered breathing, typically obstructive sleep apnea (OSA; 90 percent) or sleep-related hypoventilation (10 percent), warranting treatment with noninvasive PAP. PAP therapy should <strong>not</strong> be delayed while the patient tries to lose weight. Selection of the appropriate mode of PAP (eg, continuous PAP [CPAP], bilevel PAP [BPAP], volume cycled or hybrid modes of noninvasive ventilation) [<a href="#rid2">2</a>] and approach to initiating PAP therapy in patients with OHS are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">"Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome"</a>.)</p><p>Similar to patients with OSA who do not have OHS, patients with OHS have better outcomes when adherence to PAP is adequate [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/7702.html" rel="external">"Assessing and managing nonadherence with continuous positive airway pressure (CPAP) for adults with obstructive sleep apnea"</a>.)</p><p class="headingAnchor" id="H197285175"><span class="h3">Obesity hypoventilation plus obstructive sleep apnea (continuous positive airway pressure)</span><span class="headingEndMark"> — </span>CPAP is the typical mode chosen for treatment for OHS plus OSA, while BPAP, usually in the spontaneous–timed mode, is indicated in those who fail CPAP. (See  <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">"Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome", section on 'Obesity hypoventilation and obstructive sleep apnea'</a>.)</p><p class="headingAnchor" id="H4138268376"><span class="h3">Obesity hypoventilation plus sleep-related hypoventilation (bilevel positive airway pressure)</span><span class="headingEndMark"> — </span>Patients with OHS and sleep-related hypoventilation (absent of OSA) are, generally, initially managed with BPAP. (See  <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">"Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome", section on 'Obesity hypoventilation and sleep-related hypoventilation'</a>.)</p><p class="headingAnchor" id="H715738"><span class="h2">Weight loss and lifestyle modifications</span><span class="headingEndMark"> — </span>All patients with OHS should begin a weight loss program. Weight loss improves alveolar ventilation (sometimes normalizing the awake arterial carbon dioxide tension [PaCO<sub>2</sub>] and arterial oxygen tension [PaO<sub>2</sub>]), reduces the risk of cardiorespiratory complications (eg, pulmonary arterial hypertension and left ventricular function), improves nocturnal oxyhemoglobin saturation, decreases the frequency of respiratory events (ie, apneas, hypopneas) during sleep if the patient has coexisting OSA, and improves pulmonary function [<a href="#rid4">4-11</a>]. These benefits appear to occur regardless of whether the weight loss was due to lifestyle modification (ie, diet, exercise) or surgery. (See <a class="local">'Additional treatments targeted at weight loss'</a> below.)</p><p>Weight loss should be supervised and controlled. Rapid, unsupervised weight loss is discouraged because it is generally not sustained and may have serious side effects (eg, cholelithiasis). There are no reliable predictors of the exact amount of weight that must be lost to ameliorate nocturnal upper airway dysfunction and cardiorespiratory failure in OHS. Individuals with OHS are usually more than 50 percent above ideal body weight, and clinical experience suggests that weight loss of more than 100 pounds is often needed before clinically significant improvement is seen.</p><p>All patients with OHS should make lifestyle modifications to lose weight. Lifestyle modifications refer to various combinations of dietary change, exercise, and behavioral modification, which are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">"Obesity in adults: Dietary therapy"</a> and  <a class="medical medical_review" href="/z/d/html/5379.html" rel="external">"Obesity in adults: Role of physical activity and exercise"</a> and  <a class="medical medical_review" href="/z/d/html/5382.html" rel="external">"Obesity in adults: Behavioral therapy"</a>.)</p><p>Individuals with OHS may have more difficulty maintaining long term weight loss than persons with uncomplicated obesity because of exercise limitations related to their chronic respiratory failure. Thus, while lifestyle modifications are necessary in patients with OHS, they are seldom sufficient [<a href="#rid12">12</a>] to achieve and maintain a degree of weight loss that satisfactorily improves alveolar ventilation and sleep-related breathing disorders [<a href="#rid13">13</a>]. Thus, patients should be educated in weight loss interventions that produce significant and sustained weight loss of 25 to 30 percent of body weight (eg, bariatric surgery) [<a href="#rid1">1</a>]. (See <a class="local">'Additional treatments targeted at weight loss'</a> below.)</p><p>Compared with positive airway pressure therapy, lifestyle modification alone is less effective at improving symptoms, polysomnographic parameters, hypercapnia, and some pulmonary function measurements [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1248615993"><span class="h1">SECOND-LINE THERAPY</span><span class="headingEndMark"> — </span>Second-line therapies are reserved for patients with OHS who fail or do not tolerate first-line therapies (ie, noninvasive positive airway pressure [PAP] and weight loss measures). Bariatric surgery is also an option for those who wish to discontinue or reduce the need for PAP therapy. In general, these therapies are only considered after aggressive attempts have been made to optimize PAP therapy as they are suboptimal and associated with increased risk of adverse effects. Choosing among them depends upon factors that include the severity of OHS, degree of obesity, likelihood of efficacy or adverse effects, and patient preferences.</p><p class="headingAnchor" id="H1955826132"><span class="h2">Treatments targeted at obesity hypoventilation and sleep-disordered breathing</span></p><p class="headingAnchor" id="H5573090"><span class="h3">Tracheostomy</span><span class="headingEndMark"> — </span>Since the introduction of noninvasive PAP therapy, tracheostomy for treatment of OHS is now rarely necessary. Tracheostomy itself (without ventilation through the device) may be effective in patients with OHS and coexisting obstructive sleep apnea (OSA) because it relieves upper airway obstruction during sleep with subsequent improvement in alveolar ventilation and the arterial carbon dioxide tension (PaCO<sub>2</sub>) during wakefulness [<a href="#rid15">15</a>]. However, not all patients return to eucapnia following tracheostomy because upper airway obstruction is just one factor responsible for alveolar hypoventilation in this population; other factors (eg, decreased respiratory compliance and ventilatory muscle strength) are unaltered by tracheostomy. In keeping with this hypothesis is our experience and available data, which suggest that, despite tracheostomy placement, most patients still require nocturnal ventilation through the device for residual OSA [<a href="#rid16">16</a>].</p><p>Tracheostomy alone cannot be used to treat OHS with sleep-related hypoventilation (absent of OSA) unless the tracheostomy is also used for nocturnal ventilation.</p><p>In addition to the typical risks and complications of the procedure [<a href="#rid17">17-20</a>], tracheostomy in the individual with obesity is technically more difficult because debulking of excess adipose tissue may be required in order to securely insert a standard tracheostomy tube [<a href="#rid21">21,22</a>]. In addition, it may be associated with a higher risk of tube displacement [<a href="#rid17">17,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/4389.html" rel="external">"Tracheostomy: Rationale, indications, and contraindications"</a>.)</p><p>The role of tracheostomy and other surgical procedures (eg, maxillomandibular advancement) sometimes used in the treatment of OSA have not been rigorously tested in patients with OHS and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/97861.html" rel="external">"Surgical treatment of obstructive sleep apnea in adults", section on 'Global upper airway procedures'</a>.)</p><p class="headingAnchor" id="H3202580773"><span class="h2">Additional treatments targeted at weight loss</span><span class="headingEndMark"> — </span>For patients in whom lifestyle modifications are insufficient (see <a class="local">'Weight loss and lifestyle modifications'</a> above) and/or for patients who either want to discontinue or do not tolerate noninvasive PAP, referral to a bariatric expert is appropriate. Weight loss medications are potentially harmful and often insufficient, so we believe that they should only be used on a case-by-case basis after a careful evaluation of the potential benefits and risks to the individual patient.</p><p class="headingAnchor" id="H3541537006"><span class="h3">Bariatric surgery</span><span class="headingEndMark"> — </span>For patients with class 2 or 3 obesity who have OHS, considerable attention has been directed toward bariatric surgery, since lifestyle modifications alone are generally insufficient and pharmacological therapy is of uncertain efficacy and safety [<a href="#rid23">23</a>]. Although no study has specifically enrolled patients with OHS, improvements in gas exchange, OSA, and indices of pulmonary hypertension have been reported in individuals with obesity undergoing bariatric surgery [<a href="#rid4">4,6-8,10,11,24</a>]. However, patients with OHS may be excluded from surgery due to the presence of comorbid conditions (eg, pulmonary hypertension or obesity itself). Additionally, the response to bariatric surgery (degree of weight loss, improvement in OSA, improvement in physiologic parameters) is dependent on both individual patient variables and surgical technique. Thus, complete resolution of OHS and freedom from PAP therapy is not uniform. The indications, contraindications, techniques, and complications of bariatric surgery and the preoperative evaluation of OSA prior to bariatric surgery, including recommendations on consultation with a sleep expert and/or repeat polysomnography, are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/586.html" rel="external">"Bariatric surgery for management of obesity: Indications and preoperative preparation"</a> and  <a class="medical medical_review" href="/z/d/html/88536.html" rel="external">"Bariatric procedures for the management of severe obesity: Descriptions"</a> and  <a class="medical medical_review" href="/z/d/html/13516.html" rel="external">"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea"</a>.)</p><p>Patients should continue their noninvasive PAP therapy pre- and postoperatively. Inability to tolerate PAP therapy prior to bariatric surgery may necessitate a temporary tracheostomy either prior to or at the time of bariatric surgery [<a href="#rid25">25</a>]. Even with optimal titration of nocturnal noninvasive PAP preoperatively, patients with sleep-disordered breathing may be at further risk for hypoventilation postoperatively due to the effects of surgery, general anesthesia, or medications, such that empiric adjustments to PAP settings may be needed for a short period. Postoperative management of patients with obesity and OSA is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88610.html" rel="external">"Bariatric surgery: Postoperative and long-term management"</a> and  <a class="medical medical_review" href="/z/d/html/13518.html" rel="external">"Postoperative management of adults with obstructive sleep apnea"</a>.)</p><p class="headingAnchor" id="H1479957804"><span class="h3">Medication</span><span class="headingEndMark"> — </span>Pharmacologic therapy for weight loss should only be administered in patients with OHS who fail diet and exercise measures. However, many of the approved weight loss medications may initially only achieve weight loss of 5 to 10 kg over 3 to 12 months before the weight loss plateaus, which is typically not enough to improve or eliminate awake hypoventilation. In addition, most patients regain their weight if the medications are discontinued. Indications, efficacy, and adverse effects of weight loss pharmacotherapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy"</a>.)</p><p class="headingAnchor" id="H2012485803"><span class="h1">THERAPIES OF LIMITED VALUE OR ASSOCIATED WITH HARM</span></p><p class="headingAnchor" id="H3944558199"><span class="h2">Oxygen alone</span><span class="headingEndMark"> — </span>Oxygen should <strong>not</strong> be administered as the <strong>sole</strong> therapy for OHS. This is because oxygen may increase hypercapnia, as demonstrated in two studies of stable newly diagnosed untreated patients with OHS [<a href="#rid26">26,27</a>]. In addition, although supplemental oxygen will treat sleep-related hypoxemia, it does not address the pathophysiologic contributors to awake alveolar hypoventilation, including altered chemoresponsiveness, nocturnal upper airway occlusion, and impaired respiratory mechanics.</p><p>In situations in which a patient with OHS requires supplemental oxygen (eg, for comorbid chronic obstructive pulmonary disease, severe nocturnal desaturations unresponsive to noninvasive positive airway pressure therapy [PAP]), it should be used concurrently with optimally titrated PAP therapy. Monitoring the need for oxygen is important since hypercapnia may improve and diurnal oxygen requirements may decrease with adherence to PAP therapy [<a href="#rid28">28</a>].</p><p>If supplemental oxygen is necessary and the patient cannot tolerate PAP, the patient should be carefully monitored (clinically and/or with polysomnography) to detect potential adverse effects of worsening hypercapnia on hemodynamics and symptoms. (See  <a class="medical medical_review" href="/z/d/html/101436.html" rel="external">"Mechanisms, causes, and effects of hypercapnia", section on 'Oxygen-induced hypercapnia'</a> and  <a class="medical medical_review" href="/z/d/html/1458.html" rel="external">"The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure", section on 'Administration of oxygen'</a>.)</p><p class="headingAnchor" id="H272139773"><span class="h2">Respiratory stimulants</span><span class="headingEndMark"> — </span>Respiratory stimulants (ie, progestins and <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a>) are adjunctive therapies that are a last resort for patients who continue to have serious alveolar hypoventilation despite PAP therapy and weight loss. If prescribed, it should be done on a trial basis only in conjunction with optimally titrated PAP.</p><p>Progestins (eg, medroxyprogesterone) alone have been shown to improve but not to eliminate awake hypercapnia and hypoxemia in patients with OHS [<a href="#rid29">29,30</a>], while <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> has been shown to improve alveolar ventilation in patients with OHS [<a href="#rid15">15,31-33</a>]. However these agents do not affect all of the pathogenic contributors to OHS, in particular the recurrent upper airway collapse that occurs during sleep in patients who have coexisting obstructive sleep apnea [<a href="#rid34">34-38</a>] or the altered respiratory mechanics [<a href="#rid39">39</a>]. Leaving these contributors untreated typically results in undertreatment of OHS. In addition, progestins and acetazolamide have potentially serious side effects (eg, electrolyte disturbance, venous thromboembolism) [<a href="#rid40">40,41</a>]. The respiratory stimulant <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> has not been studied in patients with OHS. (See  <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">"Obstructive sleep apnea: Overview of management in adults", section on 'Pharmacologic'</a>.)</p><p class="headingAnchor" id="H2193021721"><span class="h1">SUPPORTIVE THERAPIES</span></p><p class="headingAnchor" id="H3010239350"><span class="h2">Avoidance of alcohol and sedatives</span><span class="headingEndMark"> — </span>Patients with OHS should be advised to avoid alcohol, benzodiazepines, opiates, muscle relaxants, and barbiturates. Failure to abstain from these agents may mitigate the benefit of positive pressure therapy. If any of these agents is considered imperative in the treatment of an individual with OHS, clinical monitoring is warranted to evaluate the impact of the medication on symptoms and arterial gas exchange. Polysomnography may be a useful adjunct to help assess nocturnal ventilation and adequacy of therapy. (See  <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">"Obstructive sleep apnea: Overview of management in adults", section on 'Alcohol, sedating, and select medications avoidance'</a>.)</p><p class="headingAnchor" id="H1031460342"><span class="h2">Treatment of comorbid conditions</span><span class="headingEndMark"> — </span>Routine treatment of comorbid conditions and the prevention of complications are also necessary in all patients with OHS. Comorbid conditions that impair ventilation or reduce the ventilatory response to hypoxemia or hypercapnia are likely to contribute to the impairment caused by obesity. As a result, the clinician should make an effort to identify and treat comorbid conditions, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic obstructive pulmonary disease (COPD) – Treatment of coexisting COPD includes the cessation of smoking and the prescription of inhaled bronchodilators and, possibly, inhaled corticosteroids. Supplemental oxygen benefits patients with hypoxemic COPD but should not be administered in OHS without coprescribing positive airway pressure (PAP) since it can worsen alveolar hypoventilation. The diagnosis and management of COPD are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a> and  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a> and  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroidism – Hypothyroidism may contribute to the chronic ventilatory failure of OHS by decreasing chemoresponsiveness, causing obstructive sleep apnea (due to macroglossia and/or upper airway dilator muscle dysfunction), or causing either a myopathy or neuropathy that affects the respiratory muscles [<a href="#rid42">42-45</a>]. These consequences of hypothyroidism may be improved with thyroid hormone replacement. In cases of subclinical hypothyroidism, which is characterized by mild elevation of serum thyroid stimulating hormone (&lt;10 mU/L) and a normal free T4 level, we prefer to monitor these patients (eg, every six months) for the development of overt hypothyroidism using clinical examination and thyroid function tests. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a>.)</p><p></p><p class="headingAnchor" id="H4121231023"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>The therapeutic goals for patients with OHS include [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Normalization of the arterial carbon dioxide tension (PaCO<sub>2</sub>) during wakefulness and sleep (ie, PaCO<sub>2</sub> &lt;45 mmHg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elimination of oxyhemoglobin desaturation during wakefulness and sleep; to avoid worsening hypercapnia, it is recommended that the provision of supplemental oxygen during positive airway pressure (PAP) therapy be the minimum amount required to maintain an oxyhemoglobin saturation of ≥90 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relief of the symptoms of OHS (typically daytime hypersomnolence).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of complications, including erythrocytosis, pulmonary hypertension, and right heart failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of underlying obstructive sleep apnea (OSA; ie, elimination of obstructive and hypopnea events) or sleep-related hypoventilation (ie, nonobstructive events).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improvement of sleep architecture and quality, reducing nocturnal work of breathing, and providing respiratory muscle rest.</p><p></p><p>While there are no standard recommendations for the follow-up of patients undergoing treatment for OHS, follow-up should include clinical evaluation of the response to noninvasive PAP and/or weight loss (eg, every six months). Notably, duration of therapy, and therefore follow-up, are typically indeterminate and often lifelong since the degree of support may change over time depending upon factors including weight loss/gain, medications, or the development or treatment of contributing comorbidities.</p><p class="bulletIndent1"><span class="glyph">●</span>Follow-up after noninvasive PAP – The follow-up of those treated with noninvasive PAP is focused on ensuring adequate settings and compliance with therapy as well as the evaluation of symptoms, repeating arterial blood gases (ABG), and, in select circumstances, repeating polysomnography, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7677.html" rel="external">"Titration of positive airway pressure therapy for adults with obstructive sleep apnea"</a> and  <a class="medical medical_review" href="/z/d/html/99556.html" rel="external">"Mode selection for titration of positive airway pressure in adults with obstructive sleep apnea", section on 'Follow-up after initial titration'</a> and  <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">"Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome", section on 'Assessing treatment response'</a> and  <a class="medical medical_review" href="/z/d/html/99556.html" rel="external">"Mode selection for titration of positive airway pressure in adults with obstructive sleep apnea"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Follow-up after weight loss – It is unusual that weight loss, even if significant, eliminates the need for nocturnal ventilation. Thus, long term PAP is still typically needed, but most patients have reduced PAP settings or can switch to continuous PAP (CPAP) if originally receiving bilevel PAP (BPAP). Reassessment of OHS is performed after significant weight loss has occurred (eg, usually within one to two years after bariatric surgery). An ABG should be performed to examine the awake partial arterial pressures of carbon dioxide (PaCO<sub>2</sub>) and oxygen (PaO<sub>2</sub>), as well as in-laboratory polysomnography to assess for accurate PAP and supplemental oxygen settings so that adjustments can be made if necessary. Early, rapid weight loss (typically 45 to 70 percent of excess body weight) during the first postoperative year after bariatric surgery is often associated with improvement of OHS [<a href="#rid47">47</a>]. However, this has not been universal and some patients have residual OSA despite amelioration of symptoms [<a href="#rid4">4,6,13,48-53</a>]. Thus, discontinuation of noninvasive PAP therapy after weight loss should <strong>not</strong> be performed unless polysomnography demonstrates that residual OSA or hypoventilation warranting therapy is absent.</p><p></p><p class="headingAnchor" id="H4211744432"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Morbidity and mortality in untreated patients with OHS is high [<a href="#rid54">54,55</a>]. OHS tends to be progressive if left untreated, with many patients developing cardiovascular complications including pulmonary hypertension and right heart failure.</p><p>The main cause of death is generally from cardiovascular disease [<a href="#rid55">55,56</a>]. The impact of therapy, particularly noninvasive positive airway pressure, on cardiovascular complications and mortality is uncertain and appears limited based upon extrapolated data from patients with obstructive sleep apnea (OSA). Even when sleep-disordered breathing is treated with positive airway pressure therapy, mortality in those with severe OHS remains substantially worse than individuals with OSA alone [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/7705.html" rel="external">"Obstructive sleep apnea and cardiovascular disease in adults"</a>.)</p><p>Hospitalization rates are higher in OHS compared with eucapnic individuals with obesity [<a href="#rid57">57</a>], and once hospitalized, patients with OHS are more likely to need intensive care unit management, be intubated, and require long-term care at discharge [<a href="#rid58">58</a>].</p><p>Individuals with OHS have considerably worse health status and access more health care resources compared to the general population, with differences apparent up to eight years before a diagnosis is made [<a href="#rid59">59</a>].</p><p>The presence of significant awake hypoxemia at diagnosis and during PAP therapy has been associated with a poor prognosis [<a href="#rid60">60,61</a>].</p><p class="headingAnchor" id="H715527"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Obesity hypoventilation syndrome (OHS; "pickwickian syndrome") exists when an individual with obesity (body mass index [BMI] &gt;30 kg/m<sup>2</sup>) has awake alveolar hypoventilation (arterial carbon dioxide tension [PaCO<sub>2</sub>] &gt;45 mmHg), which cannot be attributed to other conditions (eg, neuromuscular disease). (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/7698.html" rel="external">"Clinical manifestations and diagnosis of obesity hypoventilation syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Our approach is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with OHS, we recommend a comprehensive and multidisciplinary approach targeted at the immediate initiation of noninvasive positive airway pressure (PAP) together with lifestyle modifications for weight loss. (See <a class="local">'Positive airway pressure'</a> above and  <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">"Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with OHS who fail or do not tolerate first-line therapies in whom aggressive attempts have been made to optimize PAP therapy, options include tracheostomy for the treatment of sleep-disordered breathing and bariatric surgery or rarely medication for weight loss. In general, these therapies are suboptimal and associated with increased risk of adverse effects. Choosing among them depends upon factors including severity of OHS, degree of obesity, medical comorbidities, likelihood of efficacy or adverse effects, and patient preferences. (See <a class="local">'Weight loss and lifestyle modifications'</a> above and <a class="local">'Second-line therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapies of limited value</strong> – For patients with OHS in whom supplemental oxygen is indicated (eg, for significant sleep-related oxyhemoglobin desaturation or for hypoxemic respiratory failure), we suggest that it be administered in conjunction with noninvasive PAP, based upon the rationale that supplemental oxygen alone may worsen hypercapnia. Oxygen should <strong>not</strong> be administered as a sole therapy for OHS. Respiratory stimulants (ie, progestins and <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a>) are adjunctive therapies that are a last resort for patients who continue to have serious alveolar hypoventilation despite PAP therapy and weight loss. However, such agents are typically minimally effective and are associated with adverse effects. (See <a class="local">'Therapies of limited value or associated with harm'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive therapies</strong> – Patients with OHS should be advised to abstain from alcohol and sedatives (eg, benzodiazepines, opiates, muscle relaxants, and barbiturates), which can contribute to hypoventilation and mitigate the benefits of PAP therapy. In addition, the clinician should identify and treat comorbid conditions that may contribute to hypoventilation (eg, chronic obstructive pulmonary disease and hypothyroidism) or can complicate OHS (eg, pulmonary hypertension). (See <a class="local">'Supportive therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – Patients with OHS should be followed clinically for their response to noninvasive PAP and/or weight loss (eg, every six months). Notably, duration of therapy, and therefore follow-up, are typically indeterminate and often lifelong since the degree of support may change over time depending upon factors including weight loss/gain, medications, or the development or treatment of contributing comorbidities. (See <a class="local">'Follow-up'</a> above and  <a class="medical medical_review" href="/z/d/html/7714.html" rel="external">"Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome", section on 'Assessing treatment response'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Morbidity and mortality in untreated patients with OHS is high, with most deaths due to cardiovascular complications including pulmonary hypertension and right heart failure. The impact of therapy on cardiovascular complications and mortality is uncertain. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 200:e6.</a></li><li><a class="nounderline abstract_t">Berry RB, Chediak A, Brown LK, et al. Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes. J Clin Sleep Med 2010; 6:491.</a></li><li><a class="nounderline abstract_t">Bouloukaki I, Mermigkis C, Michelakis S, et al. The Association Between Adherence to Positive Airway Pressure Therapy and Long-Term Outcomes in Patients With Obesity Hypoventilation Syndrome: A Prospective Observational Study. J Clin Sleep Med 2018; 14:1539.</a></li><li><a class="nounderline abstract_t">Sugerman HJ, Fairman RP, Sood RK, et al. Long-term effects of gastric surgery for treating respiratory insufficiency of obesity. Am J Clin Nutr 1992; 55:597S.</a></li><li><a class="nounderline abstract_t">Nguyen NT, Hinojosa MW, Smith BR, et al. Improvement of restrictive and obstructive pulmonary mechanics following laparoscopic bariatric surgery. Surg Endosc 2009; 23:808.</a></li><li><a class="nounderline abstract_t">Martí-Valeri C, Sabaté A, Masdevall C, Dalmau A. Improvement of associated respiratory problems in morbidly obese patients after open Roux-en-Y gastric bypass. Obes Surg 2007; 17:1102.</a></li><li><a class="nounderline abstract_t">Boone KA, Cullen JJ, Mason EE, et al. Impact of Vertical Banded Gastroplasty on Respiratory Insufficiency of Severe Obesity. Obes Surg 1996; 6:454.</a></li><li><a class="nounderline abstract_t">Lumachi F, Marzano B, Fanti G, et al. Relationship between body mass index, age and hypoxemia in patients with extremely severe obesity undergoing bariatric surgery. In Vivo 2010; 24:775.</a></li><li><a class="nounderline abstract_t">Lumachi F, Marzano B, Fanti G, et al. Hypoxemia and hypoventilation syndrome improvement after laparoscopic bariatric surgery in patients with morbid obesity. In Vivo 2010; 24:329.</a></li><li><a class="nounderline abstract_t">Dávila-Cervantes A, Domínguez-Cherit G, Borunda D, et al. Impact of surgically-induced weight loss on respiratory function: a prospective analysis. Obes Surg 2004; 14:1389.</a></li><li><a class="nounderline abstract_t">Thomas PS, Cowen ER, Hulands G, Milledge JS. Respiratory function in the morbidly obese before and after weight loss. Thorax 1989; 44:382.</a></li><li><a class="nounderline abstract_t">Mandal S, Suh ES, Harding R, et al. Nutrition and Exercise Rehabilitation in Obesity hypoventilation syndrome (NERO): a pilot randomised controlled trial. Thorax 2018; 73:62.</a></li><li><a class="nounderline abstract_t">Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med 2011; 183:292.</a></li><li><a class="nounderline abstract_t">Masa JF, Corral J, Alonso ML, et al. Efficacy of Different Treatment Alternatives for Obesity Hypoventilation Syndrome. Pickwick Study. Am J Respir Crit Care Med 2015; 192:86.</a></li><li><a class="nounderline abstract_t">Rapoport DM, Garay SM, Epstein H, Goldring RM. Hypercapnia in the obstructive sleep apnea syndrome. A reevaluation of the "Pickwickian syndrome". Chest 1986; 89:627.</a></li><li><a class="nounderline abstract_t">Camacho M, Teixeira J, Abdullatif J, et al. Maxillomandibular advancement and tracheostomy for morbidly obese obstructive sleep apnea: a systematic review and meta-analysis. Otolaryngol Head Neck Surg 2015; 152:619.</a></li><li><a class="nounderline abstract_t">El Solh AA, Jaafar W. A comparative study of the complications of surgical tracheostomy in morbidly obese critically ill patients. Crit Care 2007; 11:R3.</a></li><li><a class="nounderline abstract_t">Fattahi T, Chafin C, Bunnell A. Tracheostomy in the Morbidly Obese: Difficulties and Challenges. J Oral Maxillofac Surg 2017; 75:1372.</a></li><li><a class="nounderline abstract_t">Darrat I, Yaremchuk K. Early mortality rate of morbidly obese patients after tracheotomy. Laryngoscope 2008; 118:2125.</a></li><li><a class="nounderline abstract_t">Cordes SR, Best AR, Hiatt KK. The impact of obesity on adult tracheostomy complication rate. Laryngoscope 2015; 125:105.</a></li><li><a class="nounderline abstract_t">Khoo SG, Rajaretnam N. Surgical tracheostomy in morbidly obese patients: technical considerations and a two-flap technique for access. J Laryngol Otol 2012; 126:435.</a></li><li><a class="nounderline abstract_t">Gross ND, Cohen JI, Andersen PE, Wax MK. 'Defatting' tracheotomy in morbidly obese patients. Laryngoscope 2002; 112:1940.</a></li><li><a class="nounderline abstract_t">Sugerman HJ. Surgery for morbid obesity. Surgery 1993; 114:865.</a></li><li><a class="nounderline abstract_t">Masa JF, Mokhlesi B, Benítez I, et al. Echocardiographic Changes with Positive Airway Pressure Therapy in Obesity Hypoventilation Syndrome. Long-Term Pickwick Randomized Controlled Clinical Trial. Am J Respir Crit Care Med 2020; 201:586.</a></li><li><a class="nounderline abstract_t">Sugerman HJ, Baron PL, Fairman RP, et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 1988; 207:604.</a></li><li><a class="nounderline abstract_t">Wijesinghe M, Williams M, Perrin K, et al. The effect of supplemental oxygen on hypercapnia in subjects with obesity-associated hypoventilation: a randomized, crossover, clinical study. Chest 2011; 139:1018.</a></li><li><a class="nounderline abstract_t">Hollier CA, Harmer AR, Maxwell LJ, et al. Moderate concentrations of supplemental oxygen worsen hypercapnia in obesity hypoventilation syndrome: a randomised crossover study. Thorax 2014; 69:346.</a></li><li><a class="nounderline abstract_t">Mokhlesi B, Tulaimat A, Evans AT, et al. Impact of adherence with positive airway pressure therapy on hypercapnia in obstructive sleep apnea. J Clin Sleep Med 2006; 2:57.</a></li><li><a class="nounderline abstract_t">Sutton FD Jr, Zwillich CW, Creagh CE, et al. Progesterone for outpatient treatment of Pickwickian syndrome. Ann Intern Med 1975; 83:476.</a></li><li><a class="nounderline abstract_t">Lyons HA, Huang CT. Therapeutic use of progesterone in alveolar hypoventilation associated with obesity. Am J Med 1968; 44:881.</a></li><li><a class="nounderline abstract_t">Raurich JM, Rialp G, Ibáñez J, et al. Hypercapnic respiratory failure in obesity-hypoventilation syndrome: CO₂ response and acetazolamide treatment effects. Respir Care 2010; 55:1442.</a></li><li><a class="nounderline abstract_t">Powers MA. Obesity hypoventilation syndrome: bicarbonate concentration and acetazolamide. Respir Care 2010; 55:1504.</a></li><li><a class="nounderline abstract_t">Bemand TJ, Chatoor R, Natale P, et al. Acetazolamide for metabolic alkalosis complicating respiratory failure with chronic obstructive pulmonary disease or obesity hypoventilation syndrome: a systematic review. Thorax 2023; 78:1004.</a></li><li><a class="nounderline abstract_t">Jones JB, Wilhoit SC, Findley LJ, Suratt PM. Oxyhemoglobin saturation during sleep in subjects with and without the obesity-hypoventilation syndrome. Chest 1985; 88:9.</a></li><li><a class="nounderline abstract_t">Orr WC, Imes NK, Martin RJ. Progesterone therapy in obese patients with sleep apnea. Arch Intern Med 1979; 139:109.</a></li><li><a class="nounderline abstract_t">Strohl KP, Hensley MJ, Saunders NA, et al. Progesterone administration and progressive sleep apneas. JAMA 1981; 245:1230.</a></li><li><a class="nounderline abstract_t">Cook WR, Benich JJ, Wooten SA. Indices of severity of obstructive sleep apnea syndrome do not change during medroxyprogesterone acetate therapy. Chest 1989; 96:262.</a></li><li><a class="nounderline abstract_t">Anttalainen U, Saaresranta T, Vahlberg T, Polo O. Short-term medroxyprogesterone acetate in postmenopausal women with sleep-disordered breathing: a placebo-controlled, randomized, double-blind, parallel-group study. Menopause 2014; 21:361.</a></li><li><a class="nounderline abstract_t">SHARP JT, HENRY JP, SWEANY SK, et al. THE TOTAL WORK OF BREATHING IN NORMAL AND OBESE MEN. J Clin Invest 1964; 43:728.</a></li><li><a class="nounderline abstract_t">Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354:1610.</a></li><li><a class="nounderline abstract_t">Douketis JD, Julian JA, Kearon C, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2005; 3:943.</a></li><li><a class="nounderline abstract_t">Martinez FJ, Bermudez-Gomez M, Celli BR. Hypothyroidism. A reversible cause of diaphragmatic dysfunction. Chest 1989; 96:1059.</a></li><li><a class="nounderline abstract_t">Ladenson PW, Goldenheim PD, Ridgway EC. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism. Am J Med 1988; 84:877.</a></li><li><a class="nounderline abstract_t">MASSUMI RA, WINNACKER JL. SEVERE DEPRESSION OF THE RESPIRATORY CENTER IN MYXEDEMA. Am J Med 1964; 36:876.</a></li><li><a class="nounderline abstract_t">Skatrud J, Iber C, Ewart R, et al. Disordered breathing during sleep in hypothyroidism. Am Rev Respir Dis 1981; 124:325.</a></li><li><a class="nounderline abstract_t">Randerath W, Verbraecken J, Andreas S, et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Sugerman HJ, Fairman RP, Baron PL, Kwentus JA. Gastric surgery for respiratory insufficiency of obesity. Chest 1986; 90:81.</a></li><li><a class="nounderline abstract_t">Korenkov M, Shah S, Sauerland S, et al. Impact of laparoscopic adjustable gastric banding on obesity co-morbidities in the medium- and long-term. Obes Surg 2007; 17:679.</a></li><li><a class="nounderline abstract_t">Haines KL, Nelson LG, Gonzalez R, et al. Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea. Surgery 2007; 141:354.</a></li><li><a class="nounderline abstract_t">Lettieri CJ, Eliasson AH, Greenburg DL. Persistence of obstructive sleep apnea after surgical weight loss. J Clin Sleep Med 2008; 4:333.</a></li><li><a class="nounderline abstract_t">Greenburg DL, Lettieri CJ, Eliasson AH. Effects of surgical weight loss on measures of obstructive sleep apnea: a meta-analysis. Am J Med 2009; 122:535.</a></li><li><a class="nounderline abstract_t">Grunstein RR, Stenlöf K, Hedner JA, et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007; 30:703.</a></li><li><a class="nounderline abstract_t">Dixon JB, Schachter LM, O'Brien PE, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. JAMA 2012; 308:1142.</a></li><li><a class="nounderline abstract_t">Pérez de Llano LA, Golpe R, Ortiz Piquer M, et al. Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome. Chest 2005; 128:587.</a></li><li><a class="nounderline abstract_t">Borel JC, Burel B, Tamisier R, et al. Comorbidities and mortality in hypercapnic obese under domiciliary noninvasive ventilation. PLoS One 2013; 8:e52006.</a></li><li><a class="nounderline abstract_t">Castro-Añón O, Pérez de Llano LA, De la Fuente Sánchez S, et al. Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. PLoS One 2015; 10:e0117808.</a></li><li><a class="nounderline abstract_t">Berg G, Delaive K, Manfreda J, et al. The use of health-care resources in obesity-hypoventilation syndrome. Chest 2001; 120:377.</a></li><li><a class="nounderline abstract_t">Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004; 116:1.</a></li><li><a class="nounderline abstract_t">Jennum P, Kjellberg J. Health, social and economical consequences of sleep-disordered breathing: a controlled national study. Thorax 2011; 66:560.</a></li><li><a class="nounderline abstract_t">Budweiser S, Riedl SG, Jörres RA, et al. Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation. J Intern Med 2007; 261:375.</a></li><li><a class="nounderline abstract_t">Priou P, Hamel JF, Person C, et al. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Chest 2010; 138:84.</a></li></ol></div><div id="topicVersionRevision">Topic 7713 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31368798" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20957853" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30176976" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Association Between Adherence to Positive Airway Pressure Therapy and Long-Term Outcomes in Patients With Obesity Hypoventilation Syndrome: A Prospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1733136" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term effects of gastric surgery for treating respiratory insufficiency of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18806943" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Improvement of restrictive and obstructive pulmonary mechanics following laparoscopic bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17953247" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Improvement of associated respiratory problems in morbidly obese patients after open Roux-en-Y gastric bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10729891" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Impact of Vertical Banded Gastroplasty on Respiratory Insufficiency of Severe Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20952748" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Relationship between body mass index, age and hypoxemia in patients with extremely severe obesity undergoing bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20555008" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hypoxemia and hypoventilation syndrome improvement after laparoscopic bariatric surgery in patients with morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15603656" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impact of surgically-induced weight loss on respiratory function: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2503905" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Respiratory function in the morbidly obese before and after weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28971973" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nutrition and Exercise Rehabilitation in Obesity hypoventilation syndrome (NERO): a pilot randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21037018" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Obesity hypoventilation syndrome: mechanisms and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25915102" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of Different Treatment Alternatives for Obesity Hypoventilation Syndrome. Pickwick Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516586" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hypercapnia in the obstructive sleep apnea syndrome. A reevaluation of the "Pickwickian syndrome".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644497" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Maxillomandibular advancement and tracheostomy for morbidly obese obstructive sleep apnea: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222333" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A comparative study of the complications of surgical tracheostomy in morbidly obese critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28063276" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tracheostomy in the Morbidly Obese: Difficulties and Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029859" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Early mortality rate of morbidly obese patients after tracheotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24939326" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The impact of obesity on adult tracheostomy complication rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22284768" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Surgical tracheostomy in morbidly obese patients: technical considerations and a two-flap technique for access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12439159" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 'Defatting' tracheotomy in morbidly obese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8236007" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Surgery for morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682462" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Echocardiographic Changes with Positive Airway Pressure Therapy in Obesity Hypoventilation Syndrome. Long-Term Pickwick Randomized Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3377570" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20947648" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effect of supplemental oxygen on hypercapnia in subjects with obesity-associated hypoventilation: a randomized, crossover, clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24253834" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Moderate concentrations of supplemental oxygen worsen hypercapnia in obesity hypoventilation syndrome: a randomised crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17557438" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of adherence with positive airway pressure therapy on hypercapnia in obstructive sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1101759" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Progesterone for outpatient treatment of Pickwickian syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5759632" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Therapeutic use of progesterone in alveolar hypoventilation associated with obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20979670" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hypercapnic respiratory failure in obesity-hypoventilation syndrome: CO₂response and acetazolamide treatment effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20979680" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Obesity hypoventilation syndrome: bicarbonate concentration and acetazolamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37217290" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acetazolamide for metabolic alkalosis complicating respiratory failure with chronic obstructive pulmonary disease or obesity hypoventilation syndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4006562" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Oxyhemoglobin saturation during sleep in subjects with and without the obesity-hypoventilation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/216329" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Progesterone therapy in obese patients with sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6451714" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Progesterone administration and progressive sleep apneas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2526721" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Indices of severity of obstructive sleep apnea syndrome do not change during medroxyprogesterone acetate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24253484" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Short-term medroxyprogesterone acetate in postmenopausal women with sleep-disordered breathing: a placebo-controlled, randomized, double-blind, parallel-group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14149924" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : THE TOTAL WORK OF BREATHING IN NORMAL AND OBESE MEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10560680" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk of idiopathic venous thromboembolism in users of progestagens alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15869589" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2805837" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hypothyroidism. A reversible cause of diaphragmatic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3364447" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14162894" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : SEVERE DEPRESSION OF THE RESPIRATORY CENTER IN MYXEDEMA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6792957" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Disordered breathing during sleep in hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27920092" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3720390" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gastric surgery for respiratory insufficiency of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17658030" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Impact of laparoscopic adjustable gastric banding on obesity co-morbidities in the medium- and long-term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349847" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18763424" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Persistence of obstructive sleep apnea after surgical weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19486716" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of surgical weight loss on measures of obstructive sleep apnea: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17580591" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22990273" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100142" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341888" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comorbidities and mortality in hypercapnic obese under domiciliary noninvasive ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671545" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502632" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The use of health-care resources in obesity-hypoventilation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706658" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21199816" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Health, social and economical consequences of sleep-disordered breathing: a controlled national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17391112" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348200" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
